Covaxin: Indigenous Vaccine for COVID-19
Covaxin is India's first vaccine candidate to have gone into human clinical trials. It is developed by Bharat Biotech and has been approved by the Drug Controller General of India (DCGI) for phase I and II human clinical trials.
- The SARS-CoV-2 strain was isolated in National Institute of Virology (NIV), Pune and transferred to Bharat Biotech. They developed Covaxin as an “inactivated” vaccine — one made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate. Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Reimagining India’s Strategic Outlook: From Geography to Geometry of Interests
- 2 India’s Urban Future: Towards Inclusive and Resilient Cities
- 3 AI and Cyber Threats in India: Emerging Challenges to Digital Security
- 4 India’s Female Labour Force Participation: From Workforce Exclusion to Women-Led Growth
- 5 Food Safety Regulation in India: Strengthening Consumer Protection and Public Health
- 6 Floating Solar Parks: Powering India’s Renewable Transition
- 7 India’s Arctic Ambitions: From Observer to Active Player
- 8 India and Central Asia: Strengthening India’s Extended Neighbourhood
- 9 Urban Water Security: The Imperative for Water-Wise Cities
- 10 Strengthening Food Security and Nutrition for an Inclusive India
